With the burgeoning interest in innovative treatments for type 2 diabetes and obesity treatment, a head-to-head comparison of Tirzepatide and the dual GIP and GLP-1 receptor agonist has become paramount. While both drugs function through akin mechanisms – targeting GLP-1 and glucose-dependent insulinotropic polypeptide receptors – key variation